Aktieanalys

Active Biotech Q3 2023: Rights Issue Paves the Way for Phase II in Myelofibrosis - Redeye

{newsItem.title}

Redeye Publicerad: 10 Nov 2023 07:42

Redeye comments on Active Biotech's Q3 report and the rights issue that was simultaneously announced.

Länk till analysen i sin helhet: https://www.redeye.se/research/957308/active-biotech-q3-2023-rights-issue-paves-the-way-for-phase-ii-in-myelofibrosis?utm_source=finwire&utm_medium=RSS

Nyheter om Active Biotech

Läses av andra just nu

Om aktien Active Biotech

Senaste nytt